Development of Neutralizing Antibodies in Patients with Relapsing-Remitting Multiple Sclerosis Treated with IFN-β1a
Authors:
- F. BagnatoFBF. Bagnato
- C. PozzilliCPC. Pozzilli
- E. SimeoniESE. Simeoni
- S. BastianelliSBS. Bastianelli
- M. CurrentiMCM. Currenti
- F. DE PisaFPF. DE Pisa
- C. FieschiCFC. Fieschi
- C. GasperiniCGC. Gasperini
- M. SalvettiMSM. Salvetti
- F. DianzaniFDF. Dianzani
- 1 May 1998
- journal article
- research article
- Published by SAGE Publications in Journal of Interferon & Cytokine Research
- Vol. 18 (5) , 345-350
Abstract
Sixty-eight patients with relapsing-remitting multiple sclerosis (RRMS) were treated with 3 million or 9 million IU of recombinant interferon-β1a (recIFN-β1a) s.c. three times a week for 2 years. Their sera were tested for antibodies neutralizing the IFN (NAb) in a bioassay. Sera with titers ≥1:20 were considered positive. We detected NAb in 3.2%, 13.8%, and 15.9% of the patients in sera obtained at 3, 6, and 24 months, respectively. The incidence was not related to the IFN dose. Interestingly, during the 6 month baseline period before the start of the study, relapse rates, baseline disability, nnd the volume of lesions on T2-weighted images were significantly higher in patients who developed NAb during treatment. Because of interpatient variability, no definitive relationship was observed between NAb formation and loss of clinical or magnetic resonance imaging (MRI) response.Keywords
This publication has 25 references indexed in Scilit:
- Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-α2 therapyClinical and Experimental Immunology, 1996
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Interferon beta‐lb in the treatment of multiple sclerosisNeurology, 1995
- Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: Prevalence, etiology, and managementHepatology, 1995
- Neutralizing interferon ? antibodies in melanoma patients treated with recombinant and natural interferon ?Cancer Immunology, Immunotherapy, 1994
- Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2αJournal of Hepatology, 1994
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infectionHepatology, 1990
- Resistance to Recombinant Interferon Alfa-2a in Hairy-Cell Leukemia Associated with Neutralizing Anti-Interferon AntibodiesNew England Journal of Medicine, 1988
- CLINICAL SIGNIFICANCE OF ANTI-IFN-α ANTIBODY TITRES DURING INTERFERON THERAPYThe Lancet, 1987